1	Title: Integrative genomics analysis implicates decreased FGD6 expression underlying risk of intracranial
2	aneurysm rupture
3	
4	Authors: Andrew T. Hale MD, PhD, ¹ Jing He MS, ² and Jesse Jones MD ¹
5	
6	Affiliations: ¹ Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL;
7	² Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN.
8	
9	Corresponding Author:
10	Andrew T Hale, MD, PhD
11	Department of Neurosurgery
12	University of Alabama at Birmingham
13	FOT Suite 1060, 1720 2 nd Ave S.
14	Birmingham, AL 35294
15	Andrewthale20@gmail.com
16	
17	The authors have declared that no conflict of interest exists.
18	
19	
20	

2

21 Abstract

- 22 Background: The genetic determinants and mechanisms underlying intracranial aneurysm rupture (rIA)
- 23 are largely unknown. Given the ~50% mortality rate of rIA, approaches to identify patients at high-risk will
- 24 inform screening, diagnostic, and preventative measures.
- 25 **Objective:** Our goal was to identify and characterize the genetic basis of rIA.
- 26 Methods: We perform a genome-wide association study (GWAS) use functional genomics approaches to
- 27 identify and characterize rIA-associated loci and genes. We perform a meta-analysis across 24 published
- 28 GWAS of rIA. Single nucleotide polymorphisms (SNP), gene-burden analysis, and functional genomics
- 29 identify and characterize genetic risk factors for rIA.
- 30 Results: Our cohort contains 84,353 individuals (7,843 rIA cases and 76,510 controls). We identify 5
- 31 independent genetic loci reaching genome-wide significance (p<5.0x10⁻⁸) for rIA including rs12310399
- 32 (FGD6, OR=1.16), which to our knowledge, has not been implicated in prior GWAS of rIA. We then
- 33 quantified gene-level mutation-burden across ~20,000 genes, and only FGD6 (containing 21 rIA-
- 34 associated SNPs) reached transcriptome-wide significance. Expression quantitative trait loci (eQTL)
- 35 mapping indicates that rs12310399 causes decreased *FGD6* gene expression in arterial tissue. Next, we
- 36 utilized publicly available single-cell RNA sequencing of normal human cerebrovascular cells obtained
- 37 during resection surgery and identify high expression of FGD6 in 1 of 3 arterial lineages but absent in
- 38 perivascular cells. These data suggest how alterations in FGD6 may confer risk to rIA.
- 39 Conclusion: We identify and characterize a previously unknown risk loci for rIA containing FGD6.
- 40 Elucidation of high-risk genetic loci may instruct population-genetic screening and clinical-genetic testing
- 41 strategies to identify patients predisposed to rIA.
- 42
- 43 **Funding**: No funding sources were used for the material presented herein.

3

44 Introduction

45 Intracranial aneurysms (IA) are abnormal dilations of cerebral arteries that occur in response to 46 vessel wall dysfunction. Spontaneous rupture of an IA (rIA) causes severe neurological injury and 47 death.^{1,2} IA is estimated to affect around 5% of the world's population with lifetime rupture-risk of ~25%.³ 48 However, the mortality of rIA is ~50%.⁴ While many rIA risk-factors including family history, female 49 gender, aneurysm location/size, cigarette smoking, and hypertension have been elucidated in large epidemiological studies,⁵ these factors are largely non-specific. Thus, personalized genetic approaches to 50 1) identify patients with IA, and 2) predict which patients with IA are most likely to rupture are needed. 51 52 Elucidating causal genetic factors associated with rIA has direct implications for disease prevention, diagnosis, and treatment. While rare inherited causes of IA have been described,⁶ these 53 54 patients comprise the minority of total IA disease burden.⁷ Family history of rIA in first-degree relatives, 55 even in the absence of a known IA-associated genetic syndrome, increases one's risk of being diagnosed 56 with rIA by nearly four-fold.⁸ Thus, a strong genetic component is thought to underlie IA.⁹ and unbiased. 57 genome-wide approaches to understand the germline-genetic determinants of IA formation and rupture 58 are critical to understanding IA pathophysiology and quantification of rupture risk. Since one's genetic 59 information in large part does not change over a lifetime (excluding somatic mutations), elucidating the 60 genetic architecture of rIA can inform screening, detection, and treatment (for patients at the highest risk) 61 strategies. In this study, we systematically delineate the genetic determinants of rIA using convergent 62 human-genetic and functional genomics approaches.

63

64 Methods

65 Genome wide association study analysis

Genetic data were obtained using the Cerebrovascular Disease Knowledge Portal
(cerebrovascularportal.org).¹⁰ GWAS was performed as previously described.^{11,12} Whole-genome
genotyping was performed using Illumina HumanOmniExpressExome BeadChip.¹⁰ Imputation was
performed using the 1000 genome reference panel,¹³ Haplotype Reference Consortium, or the UK10K
using IMPUTE4 software.¹⁴ Meta-analysis was performed using inverse-variance method and Cochran's
Q test (to estimate heterogeneity) with METAL.^{15,16} Age, sex, and the first twenty principal components

4

were included as covariates in logistic regression models to identify IA-associated SNPs as previously described.¹⁷ Threshold for genome-wide significance was defined after Bonferroni correction for the total number of SNPs tested ($p \le 5.0 \times 10^{-8}$). Our cohort contained patients of both European and East-Asian ancestry. Assuming a disease prevalence for IA of 5%,¹⁸ rs73392700 allele frequency of 0.12 (the most statistically-significant SNP identified in our GWAS), and genotype relative risk of 1.5, our study is appropriately powered to 1.0 (GAS power calculator from the University of Michigan, csg.sph.umich.edu). STREGA reporting guidelines for genetic association studies were followed.¹⁹

79

80 Functional genomics analysis

The latest data release of GTEx (version 8) was used.²⁰ The GTEx portal (gtexportal.org) was 81 82 used for data visualization. Expression quantitative trait loci (eQTL) analysis, which estimates the 83 functional effect of a SNP/loci on neighboring gene expression, was performed as previously 84 described.^{11,20} Splicing quantitative trait loci (sQTL) was used to determine the potential impact of a SNP 85 on alternative splicing.²¹ In addition, we used Haploreg.²² a functional genomics tool to explore the function of variants in non-coding regions of the genome. Haploreg combines data from the 1000 86 87 genomes project, Roadmap Epigenomics, and ENCODE projects to estimate the effect of SNPs on 88 functions such as chromatin state, protein-binding, and gene-expression. Data visualization was 89 performed using gtexportal.org. Finally, we utilized single-cell RNA sequencing analysis of adult human 90 brain endothelial and perivascular cells obtained from normal brain cortex biopsies obtained as previously described.23 91

92

93 Results

Our cohort contained 84,353 individuals (7,843 rIA cases and 76,510 controls) across 24
published GWAS.¹⁰ Our GWAS identified 5 independent genetic loci reaching genome-wide significance
for rIA (Figure 1A): rs73392700 (*CDKN2B*, p=4.84x10⁻¹⁷, OR=1.12), rs6841581 (*EDNRA*, p=3.52x10⁻¹⁴,
OR=0.77), rs11661542 (*RBBP8*, p=3.18x10⁻¹³, OR=0.84), rs62516550 (*RP1*, p=2.94x10⁻¹¹, OR=1.20),
and rs12310399 (*FGD6*, p=3.19x10⁻¹⁰, OR=1.16). The *FGD6* loci, to our knowledge, has not been
implicated in prior GWAS of rIA. We confirmed that population stratification and genomic control was

5

adequately achieved (i.e., no early deviation of p-values from expected, lambda statistic 1.048) bygenerating a guantile-guantile plot (Figure 1B).

102 Consistent with GWAS studies of complex and polygenic diseases, the vast majority of identified 103 genetic risk factors are located in non-coding regions of the genome, making causal inference of disease 104 mechanisms challenging.²⁴ To overcome these challenges and delineate the functional consequences of 105 rIA-associated single-nucleotide polymorphisms (SNPs), we analyzed the summative contribution of rIA associated SNPs across ~20,000 individual genes using gene-burden analysis.²⁵ Determining gene-106 107 based, rather than variant-based, associations with rIA will facilitate ease of biologic interpretation and 108 design/interpretation of mechanistic studies. Across all rIA-associated SNPs and genes tested, 958 genes 109 were associated with rIA (p< 0.05). However, after multiple-testing correction, only FGD6 (harboring 21 110 rIA-associated SNPs) reached transcriptome-wide significance.

111 To visualize the FGD6 locus for rIA-associated SNPs, we present a LocusZoom plot (Figure 2). 112 These data demonstrate the extent to which multiple variants in this locus, alone and in concert through 113 linkage disequilibrium (LD), contribute to rIA risk. To delineate the effect of rIA-associated SNPs on gene 114 expression, we present eQTL mapping across 49 tissue types using the Genotype-Tissue Expression Project (GTEx) portal²⁶ and demonstrate that the most significant rIA-associated SNP in the FGD6 loci 115 116 (rs12310399) causes decreased FGD6 gene expression most-significantly in arterial tissue (Figure 3). In addition, rs12310399 overlaps splicing QTLs for vezatin (VEZT, p< 8.20x10⁻⁹, skeletal muscle, 117 gtexportal.org), a transmembrane protein in the adherens junction that binds to myosin VIIA²⁷ and NADH 118 119 ubiquinone oxidoreductase subunit A12 (NDUFA12, p< 8.20x10⁻⁹, skeletal muscle, gtexportal.org), a 120 gene previously implicated in IA biology.²⁸ These data provide additional support for this locus and 121 suggests that multiple mechanisms are likely contributing to rIA risk. 122 While identification of new rIA-associated genes is important, it is the function of that gene in 123 relevant tissues/cells that will expand our pathophysiologic understanding of IA formation and rupture. To 124 further delineate the cellular origin and functional consequences of FGD6 expression in the 125 cerebrovascular system, we utilize scRNA-seq data derived from normal adult human brain endothelial

and perivascular cells as previously described.²³ We find that *FGD6* is highly expressed in 1 of 3 arterial

127 lineages, venules, and veins but FGD6 expression is largely undetectable across 12 perivascular cell

6

128 lineages (Figure 5A-B). These findings will facilitate additional mechanistic studies aimed at

129 understanding the molecular basis of *FGD6* dysfunction underlying rIA.

130

131 Discussion

132 We identify 5 independent genetic loci reaching genome-wide significance for rIA, including a 133 novel locus containing FGD6 not previously implicated in rIA biology. Gene-burden analysis provides 134 convergent evidence supporting the FGD6 gene in rIA risk. Functional characterization indicates that 135 genetic variation in FGD6 loci contributes to rIA risk by decreasing FGD6 gene expression in arterial 136 tissue, Utilization of single-cell RNA sequencing analysis of human brain endothelial and perivascular cells²³ characterizes *FGD6* expression across rIA-relevant neurovascular cell types where alterations in 137 138 FGD6 expression may alter cell identity and function. These data will inform detailed mechanistic analysis 139 of FGD6 in rIA biology and perhaps even treatment strategies. These data suggest that variable 140 expressivity of FDG6 causes a range of clinical features from Mendelian disease to sporadic rIA. 141 FGD6 (FYVE RhoGef and Ph domain containing protein 6) is a RhoGTPase that activates CDC42, a cell cycle-associated gene, and FGD6 has been shown to play a role in regulating 142 angiogenesis and actin cytoskeleton rearrangement,²⁹ functions consistent with rIA. Functional analysis 143 144 indicates that FGD6 regulates angiogenesis and actin cytoskeleton rearrangement.²⁹ Thus, it is 145 reasonable to posit that FGD6-dependent alterations in blood vessel integrity and/or formation may, at 146 least in part, contribute to rIA. FGD6 mediated genetic susceptibility coupled with clinical risk factors 147 (hypertension, smoking, etc.) converge to contribute summative risk for rIA. Whole-gene deletion or 148 introduction of FGD6 disease-causing mutations disrupts endothelial cell network formation which could

be rescued by introduction of the wild-type gene product.

While the focus of this manuscript is on identification and characterization of the *FGD6* loci, multiple genetic loci are contributing to rIA (Figure 1). Although the magnitude of effect is relatively small for the lead SNP in the *FGD6* loci (OR= 1.16), the clinical consequences of genetic-testing underlying rIA are more likely to be representing through assessment of polygenic risk score (PRS).³⁰ The weighted contribution of multiple loci through creation of a PRS will improve our understanding of rIA genetic architecture.³¹ In addition, combining PRS with important clinical and radiologic features of patients with

7

rIA will improve translational of these genetic findings to clinical care. As our ability to acquire, analyze,
and interpret genetic information improves, we surmise that translating genetic information into clinical
practice will become streamlined.

159 Our cohort is the largest studies of rIA to date, but additional genetic data from diverse 160 populations will increase power to detect additional risk loci and improve applicability of the genetic 161 information across diverse populations. One limitation of array based GWAS is our relative inability to 162 include rare variants, although detailed analysis of IA rare variants has been performed elsewhere.^{32,33} Multiple studies of rIA have implicated common variants underling IA risk.^{10,28,34-39} Thus, it is likely that 163 164 both common and rare variants in both coding and non-coding regions confer risk to IA, alone and in concert. In addition, recent studies suggest that somatic mutations may play a role in IA pathology,^{40,41} 165 166 which we did not assess herein, but may play a significant role in rIA pathogenesis. Analysis of lesional 167 tissue acquired through advances in endoluminal biopsy will promote our understanding of somatic 168 contribution to rIA biology.⁴² Integration of clinical and aneurysm-specific factors (size, location, etc.) will 169 enable personalized medicine approaches to IA treatment and expand the clinician's armamentarium. 170 Here we perform a large genetic study of rIA and identify and characterize a previously unknown 171 risk locus for rIA containing FGD6. Since the genetic contribution to rIA risk does not change (excluding 172 somatic mutations), approaches to quantify genetic risk of rIA may be extremely valuable for clinical 173 treatment. Integration of clinical and radiologic IA factors with genetic data will further improve our ability 174 to comprehensively evaluate rIA risk. Understanding the genetic determinants of rIA may inform gene-175 based therapies aimed at IA remodeling or obliteration. Strategies to incorporate genetic information into

176 clinical care will inform personalized medicine approaches to manage IA.

177

178 Acknowledgements

The authors would like to thank the creators of the Cerebrovascular Disease Knowledge Portal. In addition, we would like to thank GTEx which is supported by the Common Fund of the Office of the Director of the NIH, the National Cancer Institute (NCI), the National Human Genome Research Institute (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the National Institute of Neurological

8

184 Disorders and Stroke (NINDS). We would also like to thank Haploreg (Broad Institute) - which also utilizes

185 Roadmap Epigenomics, 1000 Genomes Project, and ENCODE data - for use of their resource.

187 188	References							
189	1.	Lawton MT, Vates GE. Subarachnoid Hemorrhage. N Engl J Med. 2017;377(3):257-266.						
190 191	2.	Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. Lancet. 2017;389(10069):655-666.						
192 193	3.	Korja M, Kaprio J. Controversies in epidemiology of intracranial aneurysms and SAH. <i>Nat Rev Neurol.</i> 2016;12(1):50-55.						
194	4.	Schievink WI. Intracranial Aneurysms. New England Journal of Medicine. 1997;336(1):28-40.						
195 196	5.	Teunissen LL, Rinkel GJ, Algra A, van Gijn J. Risk factors for subarachnoid hemorrhage: a systematic review. <i>Stroke.</i> 1996;27(3):544-549.						
197 198	6.	Ilinca A, Samuelsson S, Piccinelli P, Soller M, Kristoffersson U, Lindgren AG. A stroke gene panel for whole-exome sequencing. <i>European journal of human genetics : EJHG.</i> 2018.						
199	7.	Zhou S, Dion PA, Rouleau GA. Genetics of Intracranial Aneurysms. Stroke. 2018;49(3):780-787.						
200 201 202	8.	Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta- analysis. <i>The Lancet Neurology</i> . 2011;10(7):626-636.						
203 204	9.	Kleinloog R, van 't Hof FN, Wolters FJ, et al. The association between genetic risk factors and the size of intracranial aneurysms at time of rupture. <i>Neurosurgery</i> . 2013;73(4):705-708.						
205 206 207	10.	Bakker MK, van der Spek RAA, van Rheenen W, et al. Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors. <i>Nat Genet.</i> 2020;52(12):1303-1313.						
208 209	11.	Hale AT, Akinnusotu O, He J, et al. Genome-Wide Association Study Identifies Genetic Risk Factors for Spastic Cerebral Palsy. <i>Neurosurgery.</i> 2021;89(3):435-442.						
210 211	12.	Hale AT, Bastarache L, Morales DM, Wellons JC, 3rd, Limbrick DD, Jr., Gamazon ER. Multi-omic analysis elucidates the genetic basis of hydrocephalus. <i>Cell Rep.</i> 2021;35(5):109085.						
212 213 214	13.	Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample Resource (IGSR) collection of open human genomic variation resources. <i>Nucleic Acids Res.</i> 2020;48(D1):D941-d947.						
215 216	14.	Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. <i>Nature.</i> 2018;562(7726):203-209.						
217 218	15.	Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. <i>Bioinformatics</i> . 2010;26(17):2190-2191.						
219 220	16.	Hale AT, He J, Akinnusotu O, et al. Genome-wide association study reveals genetic risk factors for trigeminal neuralgia. <i>medRxiv.</i> 2021:2021.2002.2008.21251349.						
221 222	17.	Hale AT, Zhou D, Sale RL, et al. The genetic architecture of human infectious diseases and pathogen-induced cellular phenotypes. <i>medRxiv.</i> 2021:2020.2007.2019.20157404.						
223 224	18.	Caranci F, Briganti F, Cirillo L, Leonardi M, Muto M. Epidemiology and genetics of intracranial aneurysms. <i>Eur J Radiol.</i> 2013;82(10):1598-1605.						

225 226	19.	Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. <i>PLoS medicine.</i> 2009;6(2):e22.
227 228	20.	The GTEx Consortium atlas of genetic regulatory effects across human tissues. <i>Science (New York, NY).</i> 2020;369(6509):1318-1330.
229 230	21.	Li YI, Knowles DA, Humphrey J, et al. Annotation-free quantification of RNA splicing using LeafCutter. <i>Nature genetics</i> . 2018;50(1):151-158.
231 232 233	22.	Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. <i>Nucleic Acids Res.</i> 2012;40(Database issue):D930-934.
234 235	23.	Winkler EA, Kim CN, Ross JM, et al. A single-cell atlas of the normal and malformed human brain vasculature. <i>Science (New York, NY)</i> . 2022:eabi7377.
236 237 238	24.	Tak YG, Farnham PJ. Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. <i>Epigenetics Chromatin.</i> 2015;8:57.
239 240	25.	de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. <i>PLoS Comput Biol.</i> 2015;11(4):e1004219.
241 242	26.	Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. <i>Science (New York, NY).</i> 2015;348(6235):648-660.
243 244 245	27.	Guo X, Jing C, Li L, et al. Down-regulation of VEZT gene expression in human gastric cancer involves promoter methylation and miR-43c. <i>Biochemical and biophysical research communications</i> . 2011;404(2):622-627.
246 247 248	28.	Yasuno K, Bakırcıoğlu M, Low SK, et al. Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk. <i>Proc Natl Acad Sci U S A.</i> 2011;108(49):19707-19712.
249 250	29.	Huang L, Zhang H, Cheng CY, et al. A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy. <i>Nat Genet.</i> 2016;48(6):640-647.
251	30.	GWAS to the people. Nat Med. 2018;24(10):1483.
252 253	31.	Dudbridge F. Power and predictive accuracy of polygenic risk scores. <i>PLoS Genet.</i> 2013;9(3):e1003348.
254 255	32.	Kurki MI, Gaál EI, Kettunen J, et al. High risk population isolate reveals low frequency variants predisposing to intracranial aneurysms. <i>PLoS Genet.</i> 2014;10(1):e1004134.
256 257	33.	Barak T, Ristori E, Ercan-Sencicek AG, et al. PPIL4 is essential for brain angiogenesis and implicated in intracranial aneurysms in humans. <i>Nat Med.</i> 2021;27(12):2165-2175.
258 259	34.	Bilguvar K, Yasuno K, Niemelä M, et al. Susceptibility loci for intracranial aneurysm in European and Japanese populations. <i>Nat Genet.</i> 2008;40(12):1472-1477.
260 261	35.	Yasuno K, Bilguvar K, Bijlenga P, et al. Genome-wide association study of intracranial aneurysm identifies three new risk loci. <i>Nat Genet.</i> 2010;42(5):420-425.

- 36. Foroud T, Koller DL, Lai D, et al. Genome-wide association study of intracranial aneurysms
 confirms role of Anril and SOX17 in disease risk. *Stroke.* 2012;43(11):2846-2852.
- 264 37. Low SK, Takahashi A, Cha PC, et al. Genome-wide association study for intracranial aneurysm in
 265 the Japanese population identifies three candidate susceptible loci and a functional genetic
 266 variant at EDNRA. *Human molecular genetics.* 2012;21(9):2102-2110.
- 38. Foroud T, Lai D, Koller D, et al. Genome-wide association study of intracranial aneurysm identifies a new association on chromosome 7. *Stroke.* 2014;45(11):3194-3199.
- 269 39. Laarman MD, Vermunt MW, Kleinloog R, et al. Intracranial Aneurysm-Associated Single270 Nucleotide Polymorphisms Alter Regulatory DNA in the Human Circle of Willis. *Stroke.*271 2018;49(2):447-453.
- 40. Chenbhanich J, Hu Y, Hetts S, et al. Segmental overgrowth and aneurysms due to mosaic
 273 PDGFRB p.(Tyr562Cys). *Am J Med Genet A*. 2021;185(5):1430-1436.
- 41. Karasozen Y, Osbun JW, Parada CA, et al. Somatic PDGFRB Activating Variants in Fusiform
 275 Cerebral Aneurysms. *Am J Hum Genet.* 2019;104(5):968-976.
- 42. Winkler EA, Wu D, Gil E, et al. Endoluminal Biopsy for Molecular Profiling of Human Brain
 Vascular Malformations. *Neurology*. 2022.
- 43. Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. *Am J Hum Genet.* 2011;88(5):586-598.
- 44. Han B, Eskin E. Interpreting meta-analyses of genome-wide association studies. *PLoS Genet.*2012;8(3):e1002555.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.12.22272299; this version posted April 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Figure 1. Genome-wide association study (GWAS) of ruptured intracranial aneurysms (rIA). (A)

286 Manhattan plot of our rIA GWAS containing 84,353 individuals (7,843 rIA cases and 76,510 controls) and

identify 5 independent genetic loci reaching genome-wide significance (p<5.0x10⁻⁸) for rIA: rs73392700

288 (CDKN2B, OR=1.12), rs6841581 (EDNRA, OR=0.77), rs11661542 (RBBP8, OR=0.84), rs62516550

289 (RP1, OR=1.20), and rs12310399 (FGD6, OR=1.16). The horizontal red line delineates the threshold for

290 genome-wide significance ($p = 5.0 \times 10^{-8}$). (B) Quantile-Quantile (Q-Q) plot demonstrating adequate

291 genomic control for population stratification (Lambda statistic 1.048). These data are visualized using the







Figure 2. LocusZoom plot after fine-mapping of rIA-associated SNPs in the FGD6 locus.

14

Tissue	Samples	NES	p-value	m-value	Single-tissue eQTL NES (with 95% CI)
Brain - Substantia nigra	114	0.265	0.009	0.00	·
Brain - Cerebellar Hemisphere	175	0.136	0.06	0.00	
Pancreas	305	0.109	0.02	0.00	
Testis	322	0.103	1.6e-3	0.00	
Brain - Cerebellum	209	0.0914	0.2	0.00	
Brain - Hippocampus	165	0.0873	0.07	0.00	
Kidney - Cortex	73	0.0834	0.6	0.0590	
Brain - Frontal Cortex (BA9)	175	0.0734	0.07	0.00	
Esophagus - Gastroesophageal Junction	330	0.0665	0.03	0.00	
Brain - Caudate (basal ganglia)	19/	0.0647	0.07	0.00	
Brain - Cortex	205	0.0610	0.07	0.00	
Esophagus Muscularis	465	0.0584	0.03	0.00	
Proin Hypothalamus	400	0.0560	0.05	0.00	
Brain - Rypothalantus	170	0.0509	0.4	0.00	
Feenbarus, Musees	407	0.0347	0.00	0.00	
⁷ Esophagus - Mucosa Proin Antorior cingulate active (DAC4)	497	0.0470	0.09	0.00	
Brain - Anterior cingulate cortex (BA24)	147	0.0463	0.3	0.00	
	208	0.0443	0.6	0.00	
Pituitary	237	0.0409	0.5	0.00	
Adrenal Gland	233	0.0396	0.4	0.00	
Colon - Transverse	368	0.0372	0.2	0.00	
Brain - Nucleus accumbens (basal ganglia)	202	0.0350	0.3	0.00	
Uterus	129	0.0251	0.8	0.00	
Stomach	324	0.0107	0.8	0.00	— <u>—</u> —
Skin - Not Sun Exposed (Suprapubic)	517	0.00731	0.7	0.00	
Skin - Sun Exposed (Lower leg)	605	0.00448	0.8	0.00	
Prostate	221	0.00385	0.9	0.00	
Colon - Sigmoid	318	-0.00296	0.9	0.00	
Breast - Mammary Tissue	396	-0.0102	0.7	0.00	
Minor Salivary Gland	144	-0.0158	0.7	0.00	
Muscle - Skeletal	706	-0.0203	0.5	0.00	
Whole Blood	670	-0.0219	0.5	0.00	
Nerve - Tibial	532	-0.0323	0.2	0.00	
Vagina	141	-0.0341	0.6	0.00	
Heart - Left Ventricle	386	-0.0413	0.09	0.00	
Thyroid	574	-0.0434	0.2	0.00	
Brain - Spinal cord (cervical c-1)	126	-0.0568	0.5	0.00	
Brain - Amyodala	129	-0.0599	0.4	0.00	
Adipose - Visceral (Omentum)	469	-0 0744	0.03	0.00	
Ovary	167	-0.0789	0.3	0.00300	
Small Intestine - Terminal Neum	174	_0 0042	0.03	0.00	
Adinose - Subcutaneous	581	-0.0942	240-4	0.00	
	515	-0.0900	1.40.9	0.00	
Lung	373	0.0902	1.46-3	0.00	
Arteni Coroponi	012 012	-0.123	4.08-4	0.102	
Artery - Coronary	213	-0.1//	∠.0e-3	0.734	
Cells - EBV-transformed lymphocytes	147	-0.239	0.03	0.581	
Spieen	227	-0.240	1.2e-4	1.00	
Artery - Tibial	584	-0.253	1.6e-15	1.00	
Cells - Cultured fibroblasts	483	-0.299	1.7e-13	1.00	
Artery - Aorta	387	-0.339	6.5e-13	1.00	



Figure 3. Expression quantitative trait loci (eQTL) analysis of the *FGD6* locus sentinel variant

299 (rs12310399) across 49 tissues in GTEx. NES = normalized enrichment score. The m-value is the

300 posterior probability from MetaSoft which is the probability than an eQTL effect exists in the tested cross-

301 tissue analysis ^{43,44}. A m-value < 0.01 is highly suggestive that an eQTL effect does not exist, whereas a

302 m-value > 0.9 is highly predictive of an eQTL effect. Data were visualized using gtexportal.org.



- **Figure 4**. Functional mapping of the *FGD6* locus in arterial tissue. Expression quantitative trait loci
- 306 (eQTL), splicing quantitative trait loci (sQTL), and linkage disequilibrium (LD) mapping of the FGD6 locus.
- 307 Abbreviations are as follows: Transcription end site (TES), Transcription start site (TSS), Aortic artery
- 308 (ARTORT), Tibial artery (ARTTBL). Data were visualized using gtexportal.org.
- 309
- 310



311

312 Figure 5. Single-cell RNA sequencing (scRNA-seq) analysis of FGD6 across adult human brain (A) 313 endothelial and (B) perivascular cells obtained from normal resected brain tissue. Endothelial cells were 314 characterized into 3 arterial lineages (Art1-3), capillary (cap), venous, and venule cell-lineages. Blue dots 315 indicate undetectable expression of FGD6, and increasingly dark shades of orange indicate higher 316 expression of FGD6. Perivascular cells were partitioned into 7 smooth muscle (SMC1-7), 2 fibroblast 317 (FB), 2 fibromyocyte (FbM1-2), and 1 pericyte (PC) lineage. Green dots indicate undetectable expression 318 of FGD6 and red dotes indicate higher expression of FGD6. UMAP data visualization and gene-319 expression markers for cell populations was performed using the UCSC Cell Browser.